Today, GenSpera, Inc. announced that the United States Patent and Trademark Office has issued the company’s patent application, entitled “Tumor Activated Prodrugs,” as US Patent 7,635,682. The patent covers the composition and potential uses of GenSpera’s G-115 second anti-cancer drug, which is currently in development.

GenSpera, Inc. owns and controls all rights to G-115. The company anticipates a strategic partnership to maximize the drug’s value as it progresses through future clinical trials. G-115 can be selectively activated within prostate tumors by an enzyme, Prostate Specific Antigen (PSA), which is active only within prostate tissue and prostate cancer tumors. In preclinical testing, G-115 was shown to dramatically inhibit the growth of tumors in animal models of human prostate cancer.

GenSpera CEO and President, Dr. Craig Dionee, Ph.D., stated, “The company commented that the issuance of this patent further strengthens GenSpera’s intellectual property position for G-115 and its uses for prostate cancer and other prostate pathologies including enlarged prostate.

Dr. Dionne continued, “We are also pleased that the term of this patent will extend into the year 2026, which is a very important feature when we enter discussions with future development partners.”